On March 25, 2025, Humacyte, Inc. announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $2.00 per share. The aggregate gross proceeds from this offering are expected to be $50 million.
Humacyte also granted the underwriters an option for 30 days to purchase up to an additional 3,750,000 shares of common stock. All shares are being sold by Humacyte, with the closing of the offering expected around March 27, 2025.
The company intends to use the net proceeds to fund the commercialization of SYMVESS™ in the vascular trauma indication, advance its pipeline product candidates, and for general working capital purposes. This capital raise is crucial for supporting the company's transition to a commercial stage.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.